OSE Immunotherapeutics Reports 2025 Financial Results and Universal Registration Document Filing

OSE Immunotherapeutics has released its 2025 audited consolidated financial results, confirmed consistent with unaudited results published in April 2026. The inclusion of the IRIS Financing, announced in May 2026, marks a notable subsequent event. The company’s cash runway, bolstered by IRIS Financing proceeds of €19.3 million over two years, is now projected to last until December 2026. Despite uncertainties in securing long-term financing, auditors have approved the financial statements, noting potential concerns.

Key financial figures for 2025 show significant changes from the previous year. Revenues dropped sharply from €69.9 million in 2024 to €2.6 million in 2025, leading to an operating loss of €37.5 million compared to a profit of €43.7 million in 2024. Net income fell to a loss of €37.7 million. Operating cash flows also turned negative, but cash movements from investing activities showed improvement with €41.4 million.

Additionally, OSE has filed its 2025 Universal Registration Document with the AMF. This document includes the annual financial report, management report, governance report, and share buyback program details. The company continues on strategic financing efforts, targeting a broader financial strategy and exploring partnerships to extend financing beyond the 2026 horizon.